Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 19;107(5):1091–1098. doi: 10.4269/ajtmh.22-0356

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Figure 1. — Survival outcome of BALB/c mice treated with human immune or nonimmune sera 26 hours before subcutaneous challenge with virulent Rift Valley fever virus (RVFV) ZH501. Animals in each group (n = 4) were administered human sera samples with defined MP-12 neutralizing antibody (nAb) titers. The survival groups are shown based on the nAb titers measured in the mice 24 h after passive transfer. ** P < 0.01 compared with animals that received the control human nAb-negative serum. ¹Reciprocal human serum neutralizing antibody titer (PRNT₈₀) measured in the mice just before RVFV infection.